OBJECTIVE: To examine racial/ethnic longitudinal disparities in antimanic medication use among adults with bipolar-I disorder. METHODS: Observational study using administrative data from Florida's Medicaid program, July 1997 to June 2005, for enrollees diagnosed with bipolar-I disorder (N = 13,497 persons; 126,413 person-quarters). We examined the likelihood of receiving one of the following during a given quarter: (1) any antimanic agent (antipsychotic or mood stabilizer) or none, and (2) mood stabilizers, antipsychotic monotherapy, or neither. Binary and multinomial logistic regression models predicted the association between race/ethnicity and prescription fills, adjusting for clinical and demographic characteristics. Cohort indicators for year that the enrollee met study criteria were included to account for cohort effects. RESULTS: Averaging over all cohorts and quarters, compared with whites, blacks had lower odds of filling any antimanic and mood stabilizer prescriptions specifically (40%-49% and 47%-63%, respectively), but similar odds of filling prescriptions for antipsychotic monotherapy. After Bonferroni adjustment, compared with whites, there were no statistically significant disparities for Hispanics in filling prescriptions for any, or specific antimanic medications. CONCLUSIONS: Rates of antimanic medication use were low regardless of race/ethnicity. However, we found disparities in antimanic medication use for blacks compared with whites and these disparities persisted over time. We found no Hispanic-white disparities. Quality improvement efforts should focus on all individuals with bipolar disorder, but particular attention should be paid to understanding disparities in medication use for blacks.
OBJECTIVE: To examine racial/ethnic longitudinal disparities in antimanic medication use among adults with bipolar-I disorder. METHODS: Observational study using administrative data from Florida's Medicaid program, July 1997 to June 2005, for enrollees diagnosed with bipolar-I disorder (N = 13,497 persons; 126,413 person-quarters). We examined the likelihood of receiving one of the following during a given quarter: (1) any antimanic agent (antipsychotic or mood stabilizer) or none, and (2) mood stabilizers, antipsychotic monotherapy, or neither. Binary and multinomial logistic regression models predicted the association between race/ethnicity and prescription fills, adjusting for clinical and demographic characteristics. Cohort indicators for year that the enrollee met study criteria were included to account for cohort effects. RESULTS: Averaging over all cohorts and quarters, compared with whites, blacks had lower odds of filling any antimanic and mood stabilizer prescriptions specifically (40%-49% and 47%-63%, respectively), but similar odds of filling prescriptions for antipsychotic monotherapy. After Bonferroni adjustment, compared with whites, there were no statistically significant disparities for Hispanics in filling prescriptions for any, or specific antimanic medications. CONCLUSIONS: Rates of antimanic medication use were low regardless of race/ethnicity. However, we found disparities in antimanic medication use for blacks compared with whites and these disparities persisted over time. We found no Hispanic-white disparities. Quality improvement efforts should focus on all individuals with bipolar disorder, but particular attention should be paid to understanding disparities in medication use for blacks.
Authors: Lisa A Cooper; Junius J Gonzales; Joseph J Gallo; Kathryn M Rost; Lisa S Meredith; Lisa V Rubenstein; Nae-Yuh Wang; Daniel E Ford Journal: Med Care Date: 2003-04 Impact factor: 2.983
Authors: David J Kupfer; Ellen Frank; Victoria J Grochocinski; Patricia A Cluss; Patricia R Houck; Debra A Stapf Journal: J Clin Psychiatry Date: 2002-02 Impact factor: 4.384
Authors: Gail L Daumit; Rosa M Crum; Eliseo Guallar; Neil R Powe; Annelle B Primm; Donald M Steinwachs; Daniel E Ford Journal: Arch Gen Psychiatry Date: 2003-02
Authors: Jeanne Miranda; Naihua Duan; Cathy Sherbourne; Michael Schoenbaum; Isabel Lagomasino; Maga Jackson-Triche; Kenneth B Wells Journal: Health Serv Res Date: 2003-04 Impact factor: 3.402
Authors: Marguerite E Burns; Alisa B Busch; Jeanne M Madden; Robert F Le Cates; Fang Zhang; Alyce S Adams; Dennis Ross-Degnan; Stephen B Soumerai; Haiden A Huskamp Journal: Psychiatr Serv Date: 2014-03-01 Impact factor: 3.084
Authors: Marguerite E Burns; Laura Dague; Brendan Saloner; Kristen Voskuil; Nam Hyo Kim; Natalia Serna Borrero; Kevin Look Journal: Health Serv Res Date: 2020-06-23 Impact factor: 3.402
Authors: Stacie B Dusetzina; Alisa B Busch; Rena M Conti; Julie M Donohue; G Caleb Alexander; Haiden A Huskamp Journal: Pharmacoepidemiol Drug Saf Date: 2012-05-03 Impact factor: 2.890
Authors: Rayan K Al Jurdi; Herbert C Schulberg; Rebecca L Greenberg; Mark E Kunik; Ariel Gildengers; Martha Sajatovic; Benoit H Mulsant; Robert C Young Journal: J Geriatr Psychiatry Neurol Date: 2012-03 Impact factor: 2.680
Authors: Stacie B Dusetzina; Benjamin L Cook; Alisa B Busch; G Caleb Alexander; Haiden A Huskamp Journal: Psychiatr Serv Date: 2013-01 Impact factor: 3.084
Authors: Neil Krishan Aggarwal; Matthew C Pieh; Lisa Dixon; Peter Guarnaccia; Margarita Alegría; Roberto Lewis-Fernández Journal: Patient Educ Couns Date: 2015-09-03
Authors: Marguerite E Burns; Haiden A Huskamp; Jessica C Smith; Jeanne M Madden; Stephen B Soumerai Journal: Med Care Date: 2016-09 Impact factor: 2.983